Continuous Manufacturing For Small Molecule APIs Market To Reach $671.52 Million By 2030

Continuous Manufacturing For Small Molecule APIs Market Growth & Trends

The global continuous manufacturing for small molecule APIs market size is anticipated to reach USD 671.52 million by 2030, growing at a CAGR of 10.42% from 2024 to 2030, according to a report by Grand View Research, Inc. This robust expansion can be attributed to several key drivers that reflect current industry trends, advancements in technology, and changing regulatory landscapes. Continuous manufacturing processes offer significant advantages over traditional batch processing, including increased efficiency, reduced production costs, and improved product quality. The United States Food and Drug Administration (FDA) has actively promoted continuous manufacturing technologies, recognizing their potential to streamline the drug production process and enhance the overall quality of pharmaceutical products. For instance, the FDA’s “Pharmaceutical Quality for the 21st Century” initiative highlights continuous manufacturing as a key focus area, encouraging companies to adopt these innovative approaches to ensure better control over production variables.

Recent technological advancements further propel the continuous manufacturing market. Innovations in process analytical technology (PAT) enable real-time monitoring of production processes, ensuring consistent quality and compliance with regulatory standards. For instance, in July 2024, GEA introduced new continuous processing technologies designed to enhance flexibility and efficiency in pharmaceutical manufacturing. At ACHEMA 2024, GEA showcased its collaboration with Hovione, emphasizing the ConsiGma CDC flex system. This system supports both continuous and batch processes with varied throughput, improving production quality and sustainability. Their partnership aims to simplify operations and make continuous manufacturing more accessible across the industry.These technologies not only increase efficiency but also significantly shorten time-to-market for new drugs, an essential factor in an increasingly competitive pharmaceutical industry.

Government initiatives and support also play a crucial role in the growth of the continuous manufacturing market. Various countries are recognizing the need for modernization in pharmaceutical manufacturing to enhance competitiveness and improve public health outcomes. For example, the U.S. government has introduced programs aimed at facilitating the adoption of continuous manufacturing technologies, providing funding and resources to support innovation within the industry. Similarly, the European Medicines Agency (EMA) has been encouraging the use of continuous processes, promoting guidelines that facilitate the implementation of these technologies within Europe’s pharmaceutical sector.

 Request a free sample copy or view report summary: Continuous Manufacturing For Small Molecule APIs Market Report

Continuous Manufacturing For Small Molecule APIs Market Report Highlights

• Based on equipment, reactors dominated the market with a substantial share of 35.2% in 2023 and are expected to grow at the fastest CAGR of 11.0% during the forecast period  

• Based on unit operation, the synthesis segment held the largest revenue share of 39.1% in 2023 driven by technological advancements, efficiency gains, and a shift toward sustainable practices, positioning it for continued expansion in the coming years

• Based on type, generic APIs dominated the market, capturing a substantial revenue share of 10.8% in 2023

• Based on end use, CMO/CDMOs dominated the market, capturing a substantial revenue share of 70.2% in 2023

Continuous Manufacturing For Small Molecule APIs Market Segmentation

Grand View Research has segmented the global continuous manufacturing for small molecule APIs market based on equipment, unit operation, end use, type and region:

Continuous Manufacturing For Small Molecule APIs Equipment Outlook (Revenue, USD Million, 2018 - 2030)

• Reactors

• Crystallizers

• Filtration Systems

• Mixers

• Heat Exchangers

• Others (Dryers, etc.)

Continuous Manufacturing For Small Molecule APIs Unit Operation Outlook (Revenue, USD Million, 2018 - 2030)

• Synthesis

• Separation & Purification

• Drying

Continuous Manufacturing For Small Molecule APIs Type Outlook (Revenue, USD Million, 2018 - 2030)

• Generic APIs

• Innovative APIs

Continuous Manufacturing For Small Molecule APIs End Use Outlook (Revenue, USD Million, 2018 - 2030)

• CMOs/CDMOs

• Pharmaceutical Companies

• Academic & Research Institutes

Continuous Manufacturing For Small Molecule APIs Regional Outlook (Revenue, USD Million, 2018 - 2030) 

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players In The Global Continuous Manufacturing For Small Molecule APIs Market

• Pfizer Inc.

• GSK plc. (GlaxoSmithKline)

• Vertex Pharmaceuticals Incorporated

• Janssen (a subsidiary of Johnson & Johnson)

• Abbvie Inc.

• Sterling Pharma Solutions

• Evonik Industries AG

• Cambrex Corporation

• Patheon (part of Thermo Fisher Scientific)

• Hovione

• Lonza

• Phlow

• Asymchem

• GEA Group AG

• Thermo Fisher Scientific

• Corning Incorporated

• Coperion GmbH

• Continuus Pharmaceuticals

• Chemtrix

• Vapourtec Ltd

• Ehrfeld Mikrotechnik GmbH

• NiTech Solutions Ltd